Utrecht, Utrecht, The Netherlands Gilde Healthcare appeared to be the VC, which was created in 1982. The main office of represented VC is situated in the Utrecht. The fund was located in Europe if to be more exact in The Netherlands.
The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Medical Device, Hospital. Among the most popular portfolio startups of the fund, we may highlight CVRx, Evotec, Agendia.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Gilde Healthcare, startups are often financed by Morgenthaler Ventures, Ysios Capital, QuestMark Partners. The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, Morgenthaler Ventures, Gimv. In the next rounds fund is usually obtained by Morgenthaler Ventures, Gimv, Novo Holdings.
The overall number of key employees were 14.
Comparing to the other companies, this Gilde Healthcare performs on 9 percentage points more the average number of lead investments. When the investment is from Gilde Healthcare the average startup value is 50-100 millions dollars. Deals in the range of 10 - 50 millions dollars are the general things for fund. The real fund results show that this VC is 18 percentage points more often commits exit comparing to other companies. The increased amount of exits for fund were in 2018. The top activity for fund was in 2012. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Angel Tech Investors (ATI) | - |
| Apex Black | - |
| C-Bridge Capital | China, Shanghai |
| Cadence Growth Capital | Bayern, Germany, Grünwald |
| Citadele Banka AS | Latvia, Riga, Vidzeme |
| Community Development Financial Institutions Fund (CDFI Fund) | - |
| GeoEye | Dulles, United States, Virginia |
| Groupe Galeries Lafayette | France, Ile-de-France, Paris |
| Hydra Startup Studio | Montevideo, Uruguay |
| Jonathan Kalman | Haverford, Pennsylvania, United States |
| KB Partners | Highland Park, Illinois, United States |
| Nanjing Guanghe Hudong Touzi | China, Jiangsu, Nanjing |
| New York Ventures | New York, New York, United States |
| Probing VC | China, Shanghai |
| Saudi Venture Capital Company | Ar Riyad, Riyadh, Saudi Arabia |
| Sony Semiconductor | Japan, Kanagawa Prefecture, Yokohama |
| Spark Centre | - |
| Xiaomi Ventures | Beijing, Beijing, China |
| Yuxi Pacific | Pennsylvania, Philadelphia, United States |
| Ze Way Invest | France, Ile-de-France, Paris |
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Draupnir Bio | $14M | 17 Jul 2024 | Aarhus, Central Denmark Region, Denmark | ||
ADCendo | $18M | 29 May 2024 | Copenhagen, Capital Region of Denmark, Denmark | ||
Karius | $100M | 02 May 2024 | Redwood City, California, United States | ||
Argá Medtech | $63M | 27 Feb 2024 | Epalinges, Vaud, Switzerland | ||
Tagworks Pharmaceuticals | $65M | 22 Jun 2023 | Nijmegen, Gelderland, The Netherlands | ||
ADCendo | $36M | 04 Apr 2023 | Copenhagen, Capital Region of Denmark, Denmark | ||
GT Medical Technologies | $45M | 23 Mar 2023 | Tempe, Arizona, United States | ||
Noema Pharma | $112M | 07 Mar 2023 | Basel, Basel-City, Switzerland | ||
Volta Medical | $42M | 05 Jan 2023 | Marseille, Provence-Alpes-Côte d'Azur, France |
– Lumicks, an Amsterdam, The Netherlands-based life science tools company that develops innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, closed a $93m Series D funding.
– The round was led by new investors Farallon Capital Management and Lauxera Capital Partners, with participation from Softbank Vision 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments, and Irving Investors, as well as existing investor Gilde Healthcare and select members of the management team.
– The company intends to use the funds to accelerate growth initiatives including expansion of both research and development and commercial activities for the z-Movi® Cell Avidity Analyzer.
– Amphista Therapeutics from Glasgow, Scotland, UK, raised $53m in Series B funding.
– The round was co-led by Forbion and Gilde Healthcare with participation from Novartis Venture Fund, and Eli Lilly and Company, and existing investor BioMotiv and founding investor Advent Life Sciences.
– The new investment will be used to accelerate the company’s pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to extend its proprietary TPD platform.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Draupnir Bio | $14M | 17 Jul 2024 | Aarhus, Central Denmark Region, Denmark | ||
ADCendo | $18M | 29 May 2024 | Copenhagen, Capital Region of Denmark, Denmark | ||
Karius | $100M | 02 May 2024 | Redwood City, California, United States | ||
Argá Medtech | $63M | 27 Feb 2024 | Epalinges, Vaud, Switzerland | ||
Tagworks Pharmaceuticals | $65M | 22 Jun 2023 | Nijmegen, Gelderland, The Netherlands | ||
ADCendo | $36M | 04 Apr 2023 | Copenhagen, Capital Region of Denmark, Denmark | ||
GT Medical Technologies | $45M | 23 Mar 2023 | Tempe, Arizona, United States | ||
Noema Pharma | $112M | 07 Mar 2023 | Basel, Basel-City, Switzerland | ||
Volta Medical | $42M | 05 Jan 2023 | Marseille, Provence-Alpes-Côte d'Azur, France |
